Diag Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Diag Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$2.16M	Buy	+5,792	New	+$2.12M	2.47%	18

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Diag Capital Management's REGN Position: Q4 2018 in Review

Diag Capital Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q4 2018: 5,792 shares worth $2.16M. The stake represents 2.47% of the portfolio and ranks #18 among its holdings.

671 funds tracked by Wall St. Rank hold REGN as of Q4 2018.

Diag Capital Management held 5,792 shares of Regeneron Pharmaceuticals worth $2.16M as of Q4 2018.
Regeneron Pharmaceuticals was a new Diag Capital Management position in Q4 2018.
Regeneron Pharmaceuticals made up 2.47% of Diag Capital Management's portfolio in Q4 2018, its #18 holding.
671 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2018.

Based on Diag Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.